Symprove Sale to BD-capital
.jpeg)
.jpeg)
Symprove Sale to BD-capital
Spayne Lindsay is delighted to announce that it has advised Symprove, the scientifically-proven, direct-to-consumer brand disrupting the £35bn probiotics market, on the sale of a majority stake to bd-capital.
Symprove is a liquid supplement containing live, active multi-strain bacteria. Its patented delivery system allows the bacteria to “arrive, survive and thrive” in the gut, and has been recognised as uniquely effective by some of the world’s leading academics.
Interest in how to improve gut health has grown exponentially in recent years, as advances in scientific research and medicine have continued to uncover how the diversity and balance of bacteria in the microbiome affects many conditions – not only gut conditions such as IBS and IBD, but also Parkinson’s and dementia, cardiovascular conditions, mood and mental health.
Today, Symprove’s daily-use, subscription product is sold primarily through its direct-to-consumer website and is growing at more than 50% year-on-year through word-of-mouth and recommendations from doctors and nutritionists.
bd-capital was carefully selected as Symprove’s new partner based on its operationally-led approach to partnering with businesses where changing patterns of consumer behavior and technology disruption create growth opportunities.
“The team at Spayne Lindsay are engaged and fully understand this sector. We first met Spayne Lindsay in 2015 and since then they have been with us every step of the way. The team provided advice on where we needed to be as a direct-to-consumer fast-growth brand and met with us regularly, helping us to tell our story."
Our deep industry knowledge, global perspective and strong relationships make us a trusted advisor to leading consumer companies and investors
